NCT04903873: An ongoing trial by Eutilex
This trial is ongoing. It must report results 9 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04903873 |
|---|---|
| Title | An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 31, 2021 |
| Completion date | Sept. 30, 2025 |
| Required reporting date | Sept. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |